Taiho Oncology, Inc.

Taiho Oncology, Inc., a division of Taiho Pharmaceutical Co., Ltd. and Otsuka Holdings Co., Ltd., has built a world class clinical development organization that works urgently to develop innovative cancer treatments and is in the process of building commercial businesses in the USA and Europe. Taiho has an oral oncology pipeline consisting of both novel antimetabolic agents and selectively targeted agents. Advanced technology, dedicated researchers, and state of the art facilities are helping us to define the way the world treats cancer.

Taiho Patient Access Brochure

Lonsurf Flashcard

Lonsurf Patient Starter Kit Flashcard

Dosing Flashcard

www.taihooncology.com/us/

We thank our sponsors for their support of NOS activities. Their support is crucial to achieve our mission to facilitate and promote interaction among the oncology community to enhance patient care through oncology research, education and healthcare legislation.

Industry materials and presentations are not part of the Midwest Regional ASCO Review,  and do not qualify for continuing medical education (CME), continuing nursing education (CNE) or continuing education (CE) credit.

Back to Event Home Page